Literature DB >> 7160043

Binding of vinblastine to recrystallized human alpha 1-acid glycoprotein.

W H Steele, D J Haughton, H E Barber.   

Abstract

The binding of vinblastine (VLB) to recrystallized human alpha 1-acid glycoprotein (alpha 1-AGP) dissolved in phosphate-buffered saline (pH 7.4) was determined at different drug concentrations using the technique of continuous ultrafiltration. Vinblastine was extremely highly bound (greater than 99.0%) at a drug concentration of 4.0 mumol X l-1, dropping to under 60% at 65.0 mumol X l-1. Binding was best described by a two-class model with higher- (9.4 microM-1) and lower- (0.1 microM-1) affinity sites but with a similar number of binding sites (1.5 as against 1.1 lower-affinity sites). These results strongly suggest that alpha 1-AGP would be a major binding protein for VLB in plasma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7160043     DOI: 10.1007/bf00257236

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  15 in total

1.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

2.  The prognostic significance of serial seromucoid analyses in patients with cancer.

Authors:  S Harshman; V H Reynolds; T Neumaster; T Patikas; T Worrall
Journal:  Cancer       Date:  1974-08       Impact factor: 6.860

Review 3.  A decade of combination chemotherapy of advanced Hodgkin's disease.

Authors:  V T DeVita; G P Canellos; J H Moxley
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

4.  Interaction of vinblastine, vincristine and colchicine with serum proteins.

Authors:  D W Donigian; R J Owellen
Journal:  Biochem Pharmacol       Date:  1973-09-01       Impact factor: 5.858

5.  Plasma protein requirements for human platelet aggregation.

Authors:  N U Bang; R O Heidenreich; C W Trygstad
Journal:  Ann N Y Acad Sci       Date:  1972-10-27       Impact factor: 5.691

6.  The binding of vinblastine by platelets in the rat.

Authors:  H F Hebden; J R Hadfield; C T Beer
Journal:  Cancer Res       Date:  1970-05       Impact factor: 12.701

7.  Plasma protein regulation of platelet function and metabolism.

Authors:  M S Hansen; N U Bang
Journal:  Mol Cell Biochem       Date:  1979-04-02       Impact factor: 3.396

8.  The reversible binding of vinblastine to platelets: implications for therapy.

Authors:  J G Kelton; J W McDonald; R M Barr; I Walker; W Nicholson; P B Neame; C Hamid; T Y Wong; J Hirsh
Journal:  Blood       Date:  1981-03       Impact factor: 22.113

9.  Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma.

Authors:  L F Chio; C J Oon
Journal:  Cancer       Date:  1979-02       Impact factor: 6.860

10.  Serum acute-phase proteins and immunoglobulins in patients with gliomas.

Authors:  J F Weiss; R A Morantz; W P Bradley; P B Chretien
Journal:  Cancer Res       Date:  1979-02       Impact factor: 12.701

View more
  2 in total

1.  Identification of serum components that inhibit the tumoricidal activity of amphiphilic alpha helical peptides.

Authors:  K A Peck-Miller; R P Darveau; H P Fell
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  The protein binding of vinblastine in the serum of normal subjects and patients with Hodgkin's disease.

Authors:  W H Steele; D J King; H E Barber; G M Hawksworth; A A Dawson; J C Petrie
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.